中国科学院机构知识库网格
Chinese Academy of Sciences Institutional Repositories Grid
首页 机构 成果 学者
  
  1. CAS IR Grid
  2. 上海药物研究所
  3. 中国科学院上海药物研究所
  4. 新药研究国家重点实验室
Multi-Omics Integration Analysis Identifies Lipid Disorder of a Non-Alcoholic Fatty Liver Disease (NAFLD) Mouse Model Improved by Zexie-Baizhu Decoction

文献类型：期刊论文

作者Cao, Yuhan3,4; Shi, Jingying2,3; Song, Luyao3,4; Xu, Junjiu1; Lu, Henglei4; Sun, Jianhua4; Hou, Jinjun2; Chen, Jing3,4; Wu, Wanying2,3; Gong, Likun1,3,4
刊名FRONTIERS IN PHARMACOLOGY
出版日期2022-06-20
卷号13页码:15
关键词NAFLD metabolomics transcriptomics lipid metabolism traditional Chinese medicine
DOI10.3389/fphar.2022.858795
通讯作者Hou, Jinjun(lkgong@simm.ac.cn) ; Chen, Jing(wanyingwu@simm.ac.cn) ; Wu, Wanying(jingchen@simm.ac.cn) ; Gong, Likun(jinjun_hou@simm.ac.cn)
英文摘要Non-alcoholic fatty liver disease (NAFLD) is an increasingly epidemic metabolic disease with complex pathogenesis. Multi-target therapy may be an effective strategy for NAFLD treatment, and traditional Chinese medicine (TCM) characterized by multi-ingredients and multi-targets has unique advantages in long-term clinical practice. Zexie-Baizhu (ZXBZ) decoction is a Chinese classical formula to treat body fluid disorders initially. Although many bioactive monomers from Zexie and Baizhu had been discovered to improve lipid disorders, limited research studies were focused on the aqueous decoction of ZXBZ, the original clinical formulation. In the current study, we identified 94% chemical composition of ZXBZ decoction and first discovered its hepaprotective effect in a gubra-amylin NASH (GAN) diet-induced NAFLD mouse model. Based on metabolomics and transcriptomics analyses, we speculated that lipid and glucose metabolisms might be regulated by ZXBZ decoction, which was further confirmed by improved dyslipidemia and hepatic steatosis in ZXBZ groups. Consistently with cross-omics analysis, we discovered ZXBZ decoction could influence two energy sensors, Sirt1 and AMPK, and subsequently affect related proteins involved in lipid biosynthesis, catabolism, and transport. In conclusion, ZXBZ decoction regulated energy sensors, consequently impeded lipogenesis, and promoted fatty acid oxidation (FAO) to alleviate lipid disorders and protect the liver in NAFLD models, which suggested ZXBZ decoction might be a promising treatment for NAFLD.
WOS关键词ENDOPLASMIC-RETICULUM ; SIRT1 ; AMPK ; METABOLISM ; STEATOHEPATITIS ; HOMEOSTASIS ; ACTIVATION ; OXIDATION ; NETWORK ; TARGET
WOS研究方向Pharmacology & Pharmacy
语种英语
出版者FRONTIERS MEDIA SA
WOS记录号WOS:000820274100001
源URL[http://119.78.100.183/handle/2S10ELR8/301830]  
专题新药研究国家重点实验室
通讯作者Hou, Jinjun; Chen, Jing; Wu, Wanying; Gong, Likun
作者单位1.Nanjing Univ Chinese Med, Sch Chinese Mat Med, Nanjing, Peoples R China
2.Chinese Acad Sci, Shanghai Inst Mat Med, Natl Engn Res Ctr TCM Standardizat Technol, Shanghai, Peoples R China
3.Univ Chinese Acad Sci, Beijing, Peoples R China
4.Chinese Acad Sci, Shanghai Inst Mat Med, State Key Lab Drug Res, Shanghai, Peoples R China
推荐引用方式
GB/T 7714		 Cao, Yuhan,Shi, Jingying,Song, Luyao,et al. Multi-Omics Integration Analysis Identifies Lipid Disorder of a Non-Alcoholic Fatty Liver Disease (NAFLD) Mouse Model Improved by Zexie-Baizhu Decoction[J]. FRONTIERS IN PHARMACOLOGY,2022,13:15.
APA Cao, Yuhan.,Shi, Jingying.,Song, Luyao.,Xu, Junjiu.,Lu, Henglei.,...&Gong, Likun.(2022).Multi-Omics Integration Analysis Identifies Lipid Disorder of a Non-Alcoholic Fatty Liver Disease (NAFLD) Mouse Model Improved by Zexie-Baizhu Decoction.FRONTIERS IN PHARMACOLOGY,13,15.
MLA Cao, Yuhan,et al."Multi-Omics Integration Analysis Identifies Lipid Disorder of a Non-Alcoholic Fatty Liver Disease (NAFLD) Mouse Model Improved by Zexie-Baizhu Decoction".FRONTIERS IN PHARMACOLOGY 13(2022):15.

入库方式： OAI收割

来源：上海药物研究所

浏览0
下载0
收藏0
其他版本

除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。